Amgen Inc. (AMGN)
| Market Cap | 179.83B |
| Revenue (ttm) | 35.97B |
| Net Income (ttm) | 7.01B |
| Shares Out | 538.48M |
| EPS (ttm) | 12.93 |
| PE Ratio | 25.82 |
| Forward PE | 15.77 |
| Dividend | $10.08 (3.02%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 833,665 |
| Open | 330.72 |
| Previous Close | 331.49 |
| Day's Range | 330.72 - 334.38 |
| 52-Week Range | 257.05 - 346.38 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 315.31 (-5.58%) |
| Earnings Date | Feb 3, 2026 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for AMGN stock is "Hold." The 12-month stock price target is $315.31, which is a decrease of -5.58% from the latest price.
News
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif. , Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action aga...
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA® (inebilizumab-cdon) for the tre...
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMG THOUSAND OAKS, Calif. , De...
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026.
Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Dogs Of The Dow Continue Outperforming Broader Market
Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index ret...
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference at 1:45 p.m.
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 8th annual Evercore ISI HealthCONx Conference at 10:00 a.m.
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With ...
Trade Tracker: Bill Baruch buys more Amgen
Bill Baruch, founder and president at Blue Line Capital, joins CNBC's “Halftime Report” to detail his latest Amgen purchase. The Investment Committee debate the biotech sector.
Cramer's Stop Trading: Amgen
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
There Are Non-AI Stocks Worth Buying. Start With This List.
Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.
Amgen CEO talks trial results of cardiac drug Repatha
Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.
CEO of drugmaker Amgen talks new results from cholesterol drug trial
Amgen CEO Bob Bradway told CNBC's Jim Cramer that a new trial showed his company's drug can reduce the risk of heart attack. "This trial answered questions that have been on the mind of investigators ...
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif. , Nov. 8, ...
Amgen cholesterol drug cuts risk of first cardiac event by 25%
Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a lar...